Alterations in nutrient availability in the lungs during Streptococcus pneumoniae -induced pneumonia
Infection and Immunity · 11.11.2025 · 93 (11)
DOI: 10.1128/iai.00380-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection and Immunity, erschienen am 11.11.2025. Verfasst von Hansol Im und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Streptococcus pneumoniae, Pneumonia, Pneumococcal, Lung, Nutrients. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Investigator Studies Program (MISP), NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
Streptococcus pneumoniae is a leading cause of pneumonia. Importantly, the extent and impact of changes in the infected airway on bacterial nutrient availability and gene expression are not known. Utilizing untargeted UPLC-ESI-MS/MS metabolomics, we comprehensively characterized the metabolic landscape in the airway across early, mid, and severe stages of pneumococcal pneumonia. This revealed that dynamic shifts in metabolites occurred during pneumonia, with an initial influx of metabolites at the early stage, followed by declines as the disease progressed. Specific host metabolic perturbations were indicative of purine dysregulation, cellular stress, and outright tissue injury. Levels of glucose, a known modulator of pneumococcal capsule production, were highest at the early disease stage and then declined as the disease progressed, overlaying general metabolite trends. Concurrent bacterial transcriptome profiling was performed using a NanoString nCounter custom panel of 66 genes selected for their importance to metabolism, virulence, and stress response; 9% of which had disease-stage significant differences in gene expression. This analysis revealed remarkably high expression of spxB , the gene encoding pyruvate oxidase, at the severe stage of pneumonia compared to the mid-stage pneumonia, consistent with a drop in glucose levels and indicative of a shift toward mixed fermentation and the increased production of hydrogen peroxide. Our study improves our understanding of how pneumococcal infection alters the lung environment, driving profound metabolic shifts that, in turn, influence bacterial phenotypes. This detailed understanding of host-pathogen metabolic interactions offers valuable insights into novel therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Biological Science, Marshall University, West Virginia, Huntington, USA.
- Department of Microbiology and Immunology, Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Hansol Im, Carlos J Orihuela
Förderung
- Merck Investigator Studies Program (MISP)
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Im, H., Chembilikandy, V., D'Mello, A., Pearson, M., Tettelin, H., & Orihuela, C. J. (2025). Alterations in nutrient availability in the lungs during Streptococcus pneumoniae -induced pneumonia. Infection and Immunity, 93(11). https://doi.org/10.1128/iai.00380-25
Vancouver
Im H, Chembilikandy V, D'Mello A, Pearson M, Tettelin H, Orihuela CJ. Alterations in nutrient availability in the lungs during Streptococcus pneumoniae -induced pneumonia. Infection and Immunity. 2025;93(11). doi:10.1128/iai.00380-25
BibTeX
@article{Im2025,
author = {Im, Hansol and Chembilikandy, Vipin and D'Mello, Adonis and Pearson, Madison and Tettelin, Hervé and Orihuela, Carlos J},
title = {Alterations in nutrient availability in the lungs during Streptococcus pneumoniae -induced pneumonia},
journal = {Infection and Immunity},
year = {2025},
volume = {93},
number = {11},
doi = {10.1128/iai.00380-25}
}
EUVIMED